Compared to conventional primary staging of PCa, PSMA PET/CT changed N stage in 33% and M stage in 36%, resulted in a net increase in the LoC of 9% for N status and of 20% for M status, and led to a treatment category change in 36%. The gene discussed is FOLH1; the disease is posterior cortical atrophy.